Recently, another humanized IgG4 mAb designed to block TIM-3 developed by Novartis, sabatolimab, was tested in combination with spartalizumab (a humanized IgG4 mAb targeting PD-1) in patients with NSCLC who had previously received anti-PD-1/L1 therapies. This evidence concerns the gene HAVCR2 and non-small cell lung carcinoma.